What Happened

Incyte presented updated Phase 1 data at EHA 2026 for INCA033989, a mutant calreticulin-targeted monoclonal antibody, demonstrating rapid and sustained clinical and molecular responses in patients with myelofibrosis (MF) and essential thrombocythemia (ET). The drug showed broad efficacy across spleen volume, symptom burden, and anemia, with a manageable safety profile.

Who Is Affected

Patients with CALR-mutated myelofibrosis and essential thrombocythemia, particularly those resistant or intolerant to JAK inhibitors or prior cytoreductive therapy, stand to benefit from INCA033989. The drug targets the underlying biology of these conditions, offering potential disease modification.

Market Impact

• INCA033989 could fill a significant unmet need for CALR-mutated myeloproliferative neoplasms.
• Its dual efficacy in MF and ET positions it as a versatile treatment option.
• Incyte's planned pivotal studies by mid-2026 indicate a strong commitment to advancing this therapy.

What to Watch

Monitor Incyte's progress with pivotal studies for ET and MF, expected to begin by mid-2026. Regulatory engagement and further clinical data will be critical in determining the drug's path to market and its potential impact on treatment paradigms.